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Retinoid Regulation of Antiviral Innate
Immunity in Hepatocytes
Noell E. Cho,1 Bo-Ram Bang,1 Purnima Gurung,1 Meng Li,3 Dahn L. Clemens,4 T. Michael Underhill,5 Laura P. James,6
Jenifer R. Chase,7 and Takeshi Saito1,2
Persistent infection of hepatitis C virus (HCV) is one of the leading causes of end-stage liver disease (ESLD), such as decom-
pensated cirrhosis and liver cancer. Of particular note, nearly half of HCV-infected people in the United States are reported to
be heavy drinkers. This particular group of patients is known to rapidly progress to the ESLD. Although accelerated disease
progression among alcohol abusers infected with HCV is clinically well recognized, the molecular pathophysiology behind this
manifestation has not been well elucidated. Hepatocytes metabolize ethanol (EtOH) primarily through two steps of oxidative
catabolism in which alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) play central roles. The ADH-
ALDH pathway also governs the metabolism of retinol (vitamin A) to its transcriptionally active metabolite, retinoic acid
(RA). In this study, we defined that the ADH-ALDH pathway serves as a potent antiviral host factor in hepatocytes, which
regulates the expression of interferon (IFN)-stimulated genes (ISGs) by biogenesis of RA. ISGs constitute over 300 antiviral
effectors, which cooperatively govern intracellular antiviral innate immunity. Our study revealed that intracellular RA levels
greatly influence ISG expression under basal conditions. Moreover, RA augments ISG induction in response to viral infection
or exposure to IFN in a gene-specific manner. Lastly, our results demonstrated that EtOH attenuates the antiviral function of
the ADH-ALDH pathway, which suggests the possibility that EtOH-retinol metabolic competition is one of the molecular
mechanisms for the synergism between HCV and alcohol abuse in liver disease progression. Conclusions: RA plays a critical
role in the regulation of intracellular antiviral innate immunity in hepatocytes. (HEPATOLOGY 2016;63:1783-1795)
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Over 200 million people worldwide are chroni-cally infected with hepatitis C virus(HCV).(1) In the United States, at least 3.5
million people suffer from chronic HCV infection
with recent significant increase observed among intra-
venous (IV) drug users.(2,3) Of particular note, half of
the HCV-infected population in the United States has
been reported to be heavy drinkers.(4) This group of
patients exhibits pronounced HCV replication and
refractoriness to antiviral therapy, which results in a
30- and 48-fold increase in developing decompensated
cirrhosis and hepatocellular carcinoma, respectively.(5)
This synergism between chronic HCV infection and
alcohol abuse is well recognized; however, the underly-
ing molecular pathophysiology has not been well
understood.
Abbreviations: ADH, alcohol dehydrogenase; APAP, acetaminophen; ATRA, all trans retinoic acid; ALD, alcoholic liver disease; bp, base pairs;
CYP2E1, cytochrome P450-2E1; DMEM, Dulbecco’s modified Eagle’s medium; DR5, direct repeat 5; EtOH, ethanol; GC, gas chromatography; GFP,
green fluorescent protein; HCV, hepatitis C virus; HCV-SGR, HCV subgenomic replicon; HPLC-EC, high-performance liquid chromatography with
electrochemical detection; HSCs, hepatic stellate cells; IFN, interferon; ISGs, interferon-stimulated genes; IV, intravenous; Jak, Janus kinase; MOI, mul-
tiplicity of infection; NAD1, nicotinamide adenine dinucleotide; NAPQI, N-acetyl-p-benzoquinone imine; PAMPs, pathogen-associated molecular pat-
terns; PHHs, primary human hepatocytes; RA, retinoic acid; RAL, retinaldehyde; RAR, retinoic acid receptor; RARE, retinoic acid response element;
ROL, retinol; RT-PCR, reverse-transcription polymerase chain reaction; RE, retinyl ester; RIG-I, retinoic acid-inducible gene I; RXR, retinoid X
receptor; SeV, Sendai virus; STAT, signal transducer and activator of transcription; UTR, untranslated region.
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Hepatocytes play a central role in ethanol (EtOH)
metabolism through alcohol dehydrogenase (ADH)
and, to a lesser extent, through cytochrome P450-2E1
(CYP2E1) oxidation to acetaldehyde.(6) Acetaldehyde
is subsequently metabolized to acetate by aldehyde
dehydrogenase (ALDH).(6) The relevance of metabolic
by-product(s) of EtOH and/or cellular response in the
pathogenesis of HCV has not been well understood,
primarily because of the lack of appropriate research
tools. Here, we established Huh7 cell-line based sys-
tems that express individual enzymes required in
EtOH metabolism. Of great interest, our results dem-
onstrate that the ADH-ALDH pathway serves as a
potent antiviral element; whereas, CYP2E1 is a provi-
ral host factor. We also found that the antiviral pheno-
type of the ADH-ALDH pathway is significantly
attenuated in the presence of EtOH.
ADH also plays a critical role in the conversion of
retinol (ROL) to retinaldehyde (RAL), followed by
the oxidation of RAL to retinoic acid (RA) by
ALDH.(7) For ADH1, which is abundantly expressed
in hepatocytes, ROL is the far preferred substrate as
compared to EtOH. However, the ROL concentration
in serum is much lower than the ADH1 Km for ROL.
In contrast, the blood EtOH concentration of heavy
drinkers often approaches or surpasses the ADH1 Km
for EtOH, thus providing a situation in which biogen-
esis of RA is impaired.(7,8) This led us to hypothesize
that EtOH-ROL metabolic competition might be an
underlying mechanism for the synergism between
HCV and alcoholism.
Numerous studies indicate that RA exhibits antiviral
activities against a variety of pathogens.(9-11) The anti-
viral properties of RA have been mainly explained in
the context of professional innate immune cells and
adaptive immunity(12); however, the role in innate
immunity in terminally differentiated nonimmune cells
such as hepatocytes remains undefined. Interferon
(IFN)-stimulated genes (ISGs), constituting over 300
genes, represent the antiviral innate immune effectors
that cooperatively restrict the viral life cycle.(13) ISG
expression at basal levels determines cellular susceptibil-
ity to viral infection.(14) During infection, host cells
robustly induce additional ISGs upon pattern recogni-
tion receptor sensing of pathogen-associated molecular
patterns (PAMPs), such as viral genome.(15) This event
also results in the secretion of endogenous type 1 IFN,
such as IFN-b. IFN then promotes expression of the
grossly redundant ISGs in both infected and neighbor-
ing cells by activation of Janus kinase/signal transducer
and activator of transcription (Jak-STAT) signaling.
The magnitude of the additional ISG induction is a
major predictor of clinical outcome.(16) Although a few
ISGs have been reported as RA inducible,(15,17,18) the
fundamental role of RA in regulation of ISGs has not
been determined. Our findings revealed that restoration
of the ADH-ALDH pathway in Huh7 cells greatly
enhanced ISG expression under both basal and induced
conditions in a gene-specific manner, which was associ-
ated with successful clearance of the pathogen. More-
over, our study revealed that the EtOH-inducible
enzyme, CYP2E1,(19) significantly attenuates RA-
mediated gene expression and thus supports viral
replication.
In summary, our study demonstrated that impaired
biogenesis of RA leads to decreased expression of ISGs
in hepatocytes, thereby providing a molecular explana-
tion for the synergism between HCV infection and
alcoholic liver disease (ALD).
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Materials and Methods
CELLS AND TRANSFECTION
Huh7 cells were maintained as previously
described(20) and transfected with TransIT-LT1 (Mirus
Bio LLC, Madison, WI) or TransIT-messenger RNA
(Mirus Bio LLC). Huh7 stable cell lines expressing
hADH1B or hCYP2E1 were established by lentiviral
transduction (System Biosciences, Inc., Mountain
View, CA). Lentiviral transduction was carried out at
multiplicity of infection (MOI) 5 followed by Puromy-
cin selection (2 lg/mL) to established polyclonal
(pooled) cell lines. Primary human hepatocytes (PHHs)
were obtained from Life Technologies (Carlsbad, CA).
Primary mouse hepatocytes of C57BL/6 were obtained
from Non-Parenchymal Liver Cell Core at Southern
California Research Center for ALPD and Cirrhosis.
VIRUSES
Lentiviral and HCV (JFH1) particle was propagated
and tittered as described previously(20).(20) Huh7 sub-
genomic replicon cells were established through G418
(400 ug/mL) selection upon in vitro transcribed subge-
nome transfection. The HCV pseudoparticle system
was propagated as previously described.(21) Sendai virus
(SeV) was obtained from Charles River Laboratories
(Wilmington, MA), and the infection (10-100 HAU/
mL) was conducted in serum-free Dulbecco’s modified
Eagle’s medium (DMEM) for 1 hour at 378C.
CHEMICAL MEASUREMENT OF
EtOH AND ACETAMINOPHEN
PROTEIN ADDUCTS
EtOH treatments were carried out at 10, 12.5, and/
or 50 mM, which correspond to the physiological
blood-alcohol concentration among alcoholics of
0.046%, 0.057%, and 0.229%, respectively.(22) EtOH in
the cell-culture medium was measured by gas chroma-
tography (GC) similarly to a previous report.(23) Con-
centrations of acetaminophen (APAP) protein adducts
were measured by high-performance liquid chromatog-
raphy with electrochemical detection (HPLC-EC), as
described previously.(24) Acetaldehyde, acetate, all trans
retinoic acid (ATRA), and all trans ROL were obtained
from Sigma-Aldrich (St. Louis, MO). EC23 (ATRA
analog) was purchased from Tocris. RAR antagonist
(4310) was described previously.(25)
STATISTICAL ANALYSIS
P values were obtained using the Student t test, and
results were considered significant at P < 0.05.
Result
RESTORATION OF THE EtOH
METABOLIC PATHWAYS IN HUH7
CELLS
The ADH and ALDH families are comprised of 8
and 10 family members, respectively.(6) We first con-
ducted meta-analysis of National Center for Biotech-
nology Information/Gene Expression Omnibus
microarray data to determine the isoforms of ADHs
and ALDHs that are predominantly expressed in
human hepatocytes. Consistent with previous reports,
this analysis demonstrated that hepatocytes express the
following isoforms; (1) ADH: ADH1 (A, B, and C),
4, 6, and FE1; and (2) ALDH: ALDH1A1, ALDH2,
and ALDH4A1 (Supporting Fig. 1A,B).(26)
Because in vitro HCV studies are restricted to use of
Huh7 cells, we assessed expression of liver-dominant
ADHs and ALDHs in Huh7 cells. The gene and pro-
tein expression analysis demonstrated that Huh7 cells
lack expression of these ADHs and CYP2E1 (Fig.
1A,B). However, they preserved expression of
ALDHs, suggesting that reconstitution of ADHs
should restore their EtOH metabolism capability.
Among the enzymes responsible for conversion of
EtOH to acetaldehyde in hepatocytes, ADH1 is the
most abundant in hepatocytes.(7,26) Thus, ADH1 is
known to be the primary ADH involved in liver
EtOH metabolism. Next, we tested the enzymatic
activity of ADH1B (a delegate of ADH1) on EtOH
by determining the reduction rate of nicotinamide ade-
nine dinucleotide (NAD1) conversion to NADH.
NAD1 is a coenzyme required for oxidation of
EtOH, serving as an electron acceptor; and therefore
the conversion rate can be used to indirectly monitor
ADH activity.(26) Huh7 cellular lysates upon ADH1B
overexpression exhibited potent activity whereas
ADH4- and ADH6-expressing cells showed negligi-
ble activity (Fig. 1C). Next, we evaluated whether
reconstitution of ADH1B or CYP2E1 restores EtOH
metabolic function in Huh7 cells. The result showed
that overexpression of ADH1B, and CYP2E1, to a
lesser extent, restored metabolism to physiological con-
centrations of EtOH(22) (Fig. 1D).
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In addition to CYP1A2, 3A4, and 2D6, CYP2E1
is also known to catabolize xenobiotics such as APAP.
Upon metabolism of APAP, CYPs produce the elec-
trophile, N-acetyl-p-benzoquinone imine (NAPQI),
which exhibit toxicity through covalent binding to cel-
lular proteins and nucleic acids.(27) Thus, we tested
whether CYP2E1 in Huh7 cells produces APAP pro-
tein adducts using HPLC-EC. Cell lysates from
CYP2E1-expressing cells contained higher NAPQI
protein adducts compared to control condition (Fig.
1E). These results assure that Huh7 cells offer an envi-
ronment for these enzymes to be functional, although
these capacities appeared inferior to that of primary
hepatocytes likely because of the relative abundance
(Supporting Fig. 1C).
THE ADH-ALDH PATHWAY IS A
POTENT ANTIVIRAL HOST
FACTOR
Restoration of EtOH metabolic capacity in Huh7
cells enabled us to investigate the association between
EtOH metabolic pathways and the HCV life cycle.
Surprisingly, transient ADH1B overexpression in
Huh7 cells harboring HCV subgenomic replicon
(HCV-SGR) dramatically suppressed HCV replica-
tion (Fig. 2A,B). In contrast, overexpression of
CYP2E1 was associated with an enhancement of
HCV replication. Moreover, the antiviral effect
of ADH1B was reduced in the presence of EtOH
(Fig. 2B). Next, we tested whether ADH1B affects the
efficiency in establishing viral life cycle by HCV-SGR
replicon transduction assay. Transfection of HCV sub-
genome in Huh7 cells that stably express ADH1B
demonstrated a significantly lesser number of HCV-
replicating foci formation; however, the difference
between control and ADH1B cells diminished upon
EtOH treatment (Fig. 2C). These results indicate that
the ADH-ALDH pathway serves as an antiviral host
factor in the absence of EtOH. Furthermore, our
results suggest that either (1) the EtOH metabolic by-
products generated by ADH1B may offer a suitable
environment for efficient HCV replication or (2)
EtOH prohibits the biogenesis of antiviral molecules
produced by the ADH-ALDH pathway. To distin-
guish between these possibilities, we addressed
whether EtOH metabolites increase HCV replication
                                                                                                                                      
FIG. 1. Restoration of functional EtOH metabolic pathways in Huh7 cells. (A and B). Extracts from either Huh7 or PHHs were
subjected to gene expression (A) or immunoblotting (IB) (B) analysis of the indicated enzymes involved in EtOH metabolism.
GAPDH was used for normalization to compare relative expression (A). (C) Huh7 cell lysates containing overexpressed ADH iso-
zymes were incubated with NAD (3mM) in the presence or absence of EtOH (10 mM) to assess the NADH conversion rate
(lMoles/min/mL). (D) Huh7 cells expressing the indicated vectors were treated with EtOH (12.5 and 50 mM). The culture media
were used to measure EtOH concentration by GC. (E) Huh7 cells expressing CYP2E1 were treated with the indicated concentrations
of APAP. Concentrations of NAPQI adducts were determined using HPLC-EC. Abbreviation: GAPDH, glyceraldehyde 3-
phosphate dehydrogenase.
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efficiency. The results showed that neither acetalde-
hyde nor acetate treatment changed viral replication
efficiency (Supporting Fig. 2A,B).
To further understand how the ADH-ALDH path-
way suppresses HCV, we assessed the effect of
ADH1B expression on each stage of the viral life cycle.
First, an HCV pseudo particle containing a green fluo-
rescent protein (GFP) reporter was employed to test
the effect of ADH1B expression on viral entry. Under
these conditions, ADH1B expression in Huh7 cells
was found to have a negligible effect on viral entry (Fig.
2D). Next, we examined the effect of ADH1B expres-
sion on genome replication using reverse-transcription
polymerase chain reaction (RT-PCR). The abundance
of each region of the viral genome decreased with dis-
tance from the replication initiation site (50UTR
[untranslated region]) of the viral genome, especially in
ADH1B-expressing cells (Fig. 2E). This result may
suggest that the ADH-ALDH pathway restricts HCV
by promoting premature termination of genome repli-
cation. Taken together, these results indicate that the
ADH-ALDH pathway restricts HCV at the genome
replication/translation stage.
SHARED ANTIVIRAL PROPERTIES
OF LIVER-DOMINANT ADH
ISOFORMS
We extended our investigations to the other liver-
dominant ADHs to determine whether these enzymes
also suppress HCV. To accomplish this, we expressed
ADH4 and ADH6 in Huh7-SGR cells and assessed
their antiviral potency. The result showed that expres-
sion of ADH4 and ADH6 in HCV-SGR cells exhib-
ited a comparable degree of viral suppression as to that
observed with ADH1B expression (Fig. 3A). Similar
results were observed with immunofluorescent micro-
scopic analysis and protein analysis, wherein these
ADH isoforms potently inhibited HCV (Fig. 3B,C),
indicating that the antiviral activity of ADH is not
unique to ADH1B, but is shared among other ADHs.
                                                                                                                                      
FIG. 2. The ADH-ALDH pathway is a potent antiviral host factor. (A) Huh7 cells harboring HCV-SGR were transduced with the
indicted vectors for 48 hours. Extracts were subjected to immune-fluorescent analysis. Red: HCV NS3; green: Flag-ADH1 or
CYP2E1; blue: DAPI. (B) The indicated expression vectors were transfected into Huh7 cells containing HCV-SGR for 24 hours fol-
lowed by EtOH treatment for 48 hours. The extracts were subjected to immunoblotting (IB) analysis. (C) Huh7 cells expressing
ADH1B or control vector were transfected with in vitro transcribed HCV-SGR genome followed by G418 selection in the presence
or absence of EtOH (12.5 mM). Upon completion of G418 selection, the culture dishes were fixed and stained with crystal violet.
(D) Huh7 cells stably expressing ADH1B or control vector were challenged with HCV pseudo-particles containing a GFP reporter at
the indicated titer. Twenty-four hours postinfection, cells were subjected to fluorescent microscopic analysis. Green: GFP; blue:
DAPI. The GFP-positive cells at each condition are shown in %. (E) RT-PCR analysis with primer sets targeting the indicated
region of HCV genome. RNA was extracted from Huh7 cells stably expressing ADH1B or control vector 7 days after SGR-RNA
transfection. Abbreviations: DAPI, 40,6-diamidino-2-phenylindole; NS, nonstructural protein; PBS, phosphate-buffered saline.
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Analysis of ADH enzymatic activity revealed that
the different ADHs possess distinctive EtOH meta-
bolic activity (Fig. 1C). These ADHs have also been
shown to metabolize ROL,(7,26) leading to the possi-
bility that the ADH-ALDH pathway suppresses
HCV through metabolism of ROL. To test this possi-
bility, cell lysates containing these ADH isoforms were
treated with ROL in the presence of NAD, and the
enzymatic activity was assessed by the rate of NAD1
reduction to NADH. All ADHs tested were found to
exhibit comparable activity on ROL (Supporting Fig.
3A). In addition, the antiviral effect of ADH1B but
not ADH4 was antagonized by EtOH (Supporting
Fig. 3B), likely reflecting the enzymatic activity on
EtOH (Fig. 1C) as well as KiEtOH to ROL.(7) These
observations collectively suggest that the antiviral activ-
ity of ADH may be through the metabolism of ROL
to the biogenesis of RA and EtOH impairs the antivi-
ral effect of the ADH-ALDH pathway, depending on
their affinity to EtOH.
THE ADH-ALDH PATHWAY
REGULATES GENE EXPRESSION
THROUGH BIOGENESIS OF RA
To test whether ADH1B expression enables the
production of RA from ROL in Huh7 cells, a few
well-accepted RA-inducible genes’ expression were
assessed by quantitative RT-PCR. The result showed
that ADH1B-expressing cells robustly induced these
genes in response to ROL treatment (Fig. 4A). RA
regulates gene expression by binding to the hetero-
dimer nuclear receptor complex that is comprised of
retinoic acid receptor/retinoid X receptor (RAR-
RXR).(28) The RAR-RXR heterodimer binds prefer-
entially to a retinoic acid response element (RARE),
which contains two receptor cognate-binding sequen-
ces typically separated by 5 base pairs (bp), direct
repeat 5 (DR5). RA binding to the RAR leads to
recruitment of coactivators and activation of gene
transcription.(28) Therefore, we investigated whether
ADH1B expression in Huh7 cells impacts RAR-
mediated gene expression using a RARE-containing
luciferase reporter. First, a series of RARE luciferase
reporters comprising of 1, 3, and 5 bp separated
RARE (DR1, DR3, or DR5, respectively) were
expressed in Huh7 cells and the response to ATRA
treatment was monitored. Addition of ATRA selec-
tively induced significant luciferase activity only in the
DR5 RARE reporter (Supporting Fig. 4A). More-
over, the DR5 reporter was found to exhibit increased
and reduced activity in response to an RA agonist
(EC23) or an RAR antagonist (4310), respectively
(Supporting Fig. 4B,C). Given these results, the
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FIG. 3. Shared antiviral properties of liver-dominant ADHs. (A) HCV-SGR cells containing HCV IRES-dependent firefly luciferase
reporter were transduced with the indicated expression vectors along with renilla luciferase plasmid for 48 hours. The firefly luciferase
values were normalized with renilla luciferase and presented as relative luciferase unit (RLU). *P < 0.01. (B and C) HCV-SGR cells
were transfected with the indicated expression vectors for 48 hours followed by immunofluorescent microscopic analysis (green: HCV-
NS3; red: Flag; blue: DAPI) (B) or immunoblotting (IB) analysis of the indicated proteins (C). IFNb 10 IU/mL served as positive
control for HCV suppression (A-C). Abbreviations: DAPI, 40,6-diamidino-2-phenylindole; GAPDH, glyceraldehyde 3-phosphate
dehydrogenase; NS, nonstructural protein.
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RARE-DR5 reporter was employed as a surrogate to
follow RAR activity. After cotransfection of the
RARE-DR5 into Huh7 cells and treatment with
ROL, coexpression of ADH1B induced activation of
RARE-DR5 (Fig. 4B). In addition, both gene expres-
sion analysis and reporter assay results showed that
ADH1B expression enhances RA-gene regulation
even under the basal condition. We speculate that this
is likely because of the metabolism of up to 50 nM of
ROL in standard 10% fetal bovine serum DMEM by
the ADH1B-ALDH pathway. To further test the
influence of the ADH1B-ALDH pathway in gene
regulation, a quantitative RT-PCR array comprising
RA-regulated genes was employed (Fig. 4C,D). The
result demonstrated that ADH1B expression globally
up-regulates RA-inducible genes at the basal condi-
tion, and the degree of the up-regulation was signifi-
cantly higher than that of exogenous ROL-treated
control Huh7 cells. Next, we compared the gene
expression changes observed in Huh7 cells that
express ADH1B to that of PHH treated with ATRA.
These results showed identical patterns (Fig. 4C,D),
thereby indicating that reconstitution of ADH1B in
Huh7 cells leads to production of RA from ROL.
This notion is also well supported by the fact that the
control cells minimally changed the expression of RA-
regulated genes even in response to exogenous ROL
(Fig. 4A-C).
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FIG. 4. Reconstitution of the ADH-ALDH pathway restores biogenesis of RA. (A) Huh7 cells expressing ADH1B or control vector
were treated with DMSO (vehicle) or ROL (1 lM) for 16 hours. Extracts were subjected to quantitative RT-PCR analysis of the
indicated RA-inducible gens. (B) Huh7 cells were cotransfected with the indicated expression vectors, a firefly luciferase reporter regu-
lated by RARE-DR5, and a renilla luciferase vector. Twenty-four hours after transfection, cells were treated with ROL (1 lM),
ATRA (0.1 lM), or DMSO for 36 hours followed by dual luciferase assay. (C and D) Extracted RNA from Huh7 cells stably
expressing ADH1B or control vector (C) or PHHs (D) were subjected to quantitative RT-PCR array of RA-regulated genes. The
heat map represents the relative abundance of the indicated genes. Cells were treated with either ROL (1 lM) (C), ATRA (0.1 lM)
(D), or DMSO (control) for 16 hours before RNA extraction. *P < 0.01. Abbreviations: DMSO, dimethyl sulfoxide; RLU, relative
luciferase unit.
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CRITICAL ROLE OF THE ADH-
ALDH PATHWAY FOR THE ISG
EXPRESSION
Next, we directly tested whether RA alone was suffi-
cient to suppress HCV. For this purpose, HCV-SGR
cells were treated with RA and this led to dramatic
inhibition of viral replication (Fig. 5A). RA is known
to play an important role in a variety of cellular func-
tions, including cell proliferation, death, and differen-
tiation.(8) To better understand the mechanisms
underlying RA suppression of HCV replication, we
initially tested whether the ADH-ALDH pathway
influences cell growth and/or susceptibility to cell
death, which may nonspecifically influence viral repli-
cation given that the life cycle heavily relies on the cel-
lular machinery. Expression of ADH1B neither
changed cell growth/proliferation nor cell viability
(Supporting Fig. 5A,B). These results led us to
hypothesize that the ADH-ALDH pathway plays a
role in the regulation of antiviral host factors such as
ISGs for suppression of HCV.
Clinical studies reported that RA enhances the
response to IFN-based antiviral therapy.(11,29) These
observations suggest that expression of ISGs could be
governed, at least partially, by RA. To further explore
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FIG. 5. Potent anti-HCV suppression by RA and its enhancement of ISG expression. (A) Huh7 HCV-SGR cells were treated with
ATRA (0.1 lM) or IFNb (10 IU/mL) for 72 hours. Extracts were subjected to immunoblotting (IB) analysis of the indicated pro-
teins. (B) Quantitative RT-PCR analysis of RNA extracted from PHHs pretreated with ATRA (0.1 lM) or vehicle for 16 hours fol-
lowed by IFNb (100 IU/mL) for 8 hours. (C and E) RT-PCR for ISG expression analysis. Huh7 cells stably expressing ADH1B
were transfected with HCV-PAMP-RNA (1 lg/5 3 105cells) for indicated hours (C) or treated with IFNb (100 IU/mL) for 8 hours
(E). *P < 0.01. (D and F) IB analysis of ISG expression. Huh7 cells stably expressing ADH1B were transfected with HCV-PAMP-
RNA (0, 2, 3, and 4 lg/5 3 105cells) for 24 hours (D) or treated with IFNb (0, 1, 10, and 100 IU/mL) (F). Abbreviations: DMSO,
dimethyl sulfoxide; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; NS, nonstructural protein; OAS1, 2050-oligoadenylate syn-
thetase 1; PBS, phosphate-buffered saline; RLU, relative luciferase unit.
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this hypothesis, we conducted a bioinformatics search
of ISG (446 genes) promoter and found that 88% of
the regulatory region of ISGs contain RARE-DR5
sequence (Supporting Table 1). This observation sug-
gests that up-regulation of ISGs by RA may underlie
the ADH-ALDH-mediated suppression of HCV.
To further test this idea, we first investigated
whether RA augments the expression of ISGs in ter-
minally differentiated PHHs. These experiments
showed that ATRA treatment increased the basal
expression level of, at least, a few selected ISGs (Fig.
5B). In addition, the RA treatment significantly
enhanced ISG expression in response to type 1 IFN,
well supporting aforementioned clinical observations
(Fig. 5B). Similarly, the synthetic ATRA analog
(EC23) enhanced the IFN-mediated ISG induction in
PHHs (Supporting Fig. 5C). These observations with
noncancerous primary cells further indicate the critical
roles of RA in ISG expression in hepatocytes.
Next, we tested whether the ADH-ALDH pathway
enhances expression of ISGs in Huh7 cells. Gene
expression analyses showed that ADH1B expression
increases ISG expression under basal conditions (Fig.
5C,E). We also tested whether ADH1B expression
augments ISG expression in the induced condition
with HCV-PAMP-RNA or IFNb treatment. These
are the ligands of two distinct ISG induction pathways:
retinoic acid-inducible gene I (RIG-I) or the Jak-
STAT pathway,(15) which leads to robust induction of
ISGs during infection in infected or neighboring cells,
respectively. The result showed that ADH1B expres-
sion substantially increased ISG expression in response
to these ligands at both the message (Fig. 5C,E) and
protein level (Fig. 5D,F). Last, we also found that
ADH1B expression has negligible effect on the signal-
ing activation potency by these ligands (Supporting
Fig. 5D,E), suggesting that the augmentation of ISG
expression by RA is likely at the promoter level.
SELECTIVE UP-REGULATION OF
ISGs BY THE ADH-ALDH
PATHWAY
Given chromatin remodeling activity of RAR-RXR,
we hypothesized that RA regulates ISG expression at
the promoter level.(28) Thus, we speculated that the
effect of the ADH-ALDH pathway on ISG induction
is highly dependent on the accessibility of activated
RAR-RXRs to individual gene promoters, rather than
indiscriminate global gene up-regulation. Thus, we
assessed the pattern of ISG expression in ADH1B-
expressing cells using a quantitative RT-PCR array. In
agreement with our hypothesis, ADH1B-expressing
cells enhanced ISG expression in a gene-specific man-
ner under both basal conditions and during acute
HCV (JFH-1) infection (Fig. 6A). Of note, the up-
regulated ISGs include well-studied anti-HCV genes,
such as IFIT1 and IFITM1. Furthermore, HCV repli-
cation efficiency in ADH1B-expressing cells demon-
strated an inverse association with the degree of ISG
inducibility (Fig. 6B,C). Last, we challenged Huh7
cells expressing ADH1B with SeV, which induces
ISGs in a RIG-I signaling-dependent manner similar
to HCV.(15) ADH1B expression was found to attenu-
ate viral replication efficiency, which is correlated with
degree of ISG induction (Supporting Fig. 6A,B).
These observations indicate that the ADH-ALDH
pathway restricts viral infection through augmentation
of ISG expression at the gene promoter/enhancer
level.
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FIG. 6. Selective up-regulation of ISGs governed by the ADH-
ALDH pathway protect hepatocytes from HCV infection. (A and
C) Huh7 cells stably expressing ADH1B or control vector were
infected with HCV (JFH1 MOI: 0.5) for 24 and 48 hours. RNA
was extracted 24 hours postinfection (HPI) and used for quantita-
tive RT-PCR array for the detection of a panel of ISGs (A); RNA
and protein extracts were subjected to immunoblotting (IB) analy-
sis (B) or quantitative RT-PCR (C) for detection of viral products.
*P < 0.01. Abbreviation: NS, nonstructural protein.
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TWO DISTINCT EtOH
METABOLIZING PATHWAYS
IMPAIR RA REGULATION OF
INTRACELLULAR INNATE
IMMUNITY
Our results suggest that the impairment of RA-
mediated ISG regulation in hepatocytes serves as, at
least in part, an underlying mechanism for pronounced
HCV replication among alcoholics. To further test this
idea, we assessed whether EtOH attenuates RAR-
mediated gene regulation. Indeed, the analysis with the
RARE-DR5 reporter system (Supporting Fig. 7A) and
quantitative RT-PCR analysis (Fig. 7A) demonstrated
that EtOH impaired RA gene regulation in a dose-
dependent manner. Accordingly, the cell lysates from
ADH1B-expressing cells demonstrated comparable
enzymatic activity on both EtOH and ROL, especially
at higher concentrations (Fig. 7B). Moreover, the effect
of ADH1B in enhancing ISG expression was attenuated
in the presence of EtOH (Supporting Fig. 7B). These
observations suggest that EtOH-ROL competition
attenuates RA-mediated ISG expression.
Recent evidence has shown that CYP2E1 potently
catabolize RA to transcription inactive polar metabo-
lites.(30) CYP2E1 is an EtOH-inducible enzyme that
plays a role in EtOH metabolism(19) (Supporting Fig.
7C and Fig. 1D). Of note, our results (Fig. 2B) demon-
strated that HCV replication was enhanced upon
CYP2E1 expression. Thus, we hypothesized that
CYP2E1 expression in hepatocytes can be a secondary
mechanism that impairs RA regulation of ISG expres-
sion. An assay utilizing the RARE-DR5 reporter
showed that RA-mediated gene regulation was signifi-
cantly attenuated in the presence of CYP2E1 both under
basal and induced conditions (Fig. 7C and Supporting
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FIG. 7. EtOH deregulation of retinoid homeostasis through two distinct mechanisms. (A) Quantitative RT-PCR analysis of RA-
inducible genes. Mouse primary hepatocytes were treated with EtOH for 60 hours. *P < 0.01. (B) Cell lysates expressing ADH1B or
control cells were incubated with NAD (3 mM) and indicated ADH substrates. ADH activity was calculated by the rate of NAD1
to NADH conversion (lMoles/min/mL). (C) RARE-DR5 dual luciferase assay. Huh7 cells were cotransfected with the indicated
CYP expression vectors, RARE DR5 luciferase, and renilla reporter followed by RA for 36 hours. *P < 0.01. CYP26A1: positive con-
trol. CYP27A1, which catabolizes vitamin D, was employed as a negative control. (D) immunoblotting (IB) analysis of HCV protein
expression. Huh7 cells were transfected with CYP2E1 or control vector for 24 hours followed by HCV JFH1 infection for 48 hours.
(E) Quantitative RT-PCR of the indicated ISG expression. PHHs were treated with EtOH for 24 hours followed by IFNb (50 IU/
mL) for 8 hours. *P < 0.01. Abbreviations: CRABP2, cellular retinoic acid binding protein 2; DMSO, dimethyl sulfoxide; GAPDH,
glyceraldehyde 3-phosphate dehydrogenase; NS, nonstructural protein; OAS1, 2050-oligoadenylate synthetase 1; PBS, phosphate-
buffered saline; RLU, relative luciferase unit.
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Fig. 7D). Interestingly, our observation suggests that
CYP2E1 catabolic activity on ATRA is nearly compara-
ble to that of CYP26A1, which is the most critical RA-
catabolizing enzyme with the Km/RA 10 nM.(31) This
suggests that CYP2E1 may preferentially catabolize RA,
as compared to other substrates such as EtOH or
APAP, and may play a role in the impairment of ISG
expression. Consistent with our findings with the HCV-
SGR system (Fig. 2B), expression of CYP2E1 substan-
tially increased susceptibility to HCV infection
(Fig. 7D).
Last, we tested the effect of EtOH in ISG expres-
sion with human primary hepatocytes, in which both
EtOH-ROL competition on the ADH-ALDH path-
way and CYP2E1 induction contribute to depletion of
RA. The results showed EtOH treatment dramatically
impaired expression of ISGs (Fig. 7E).
Discussion
Alcohol is the most common intoxicating substance in
the United States. Alcoholics are known to have a signifi-
cantly higher risk of acquiring HCV, owing to the high
prevalence of IV drug use in this population.(32) The com-
bination of HCV infection and alcohol abuse rapidly pro-
gress to end-stage liver diseases(5,33); however, the
molecular mechanism underlying this phenomenon has
been unclear.
Our study demonstrated that the ADH-ALDH
pathway is a potent antiviral pathway. We also found
that the antiviral effect of ADH-ALDH pathway is
mediated by the metabolism of ROL to the biogenesis
of RA. Moreover, the antiviral property of the ADH-
ALDH pathway was diminished in the presence of
physiological concentration of EtOH among alco-
holics,(34) likely owing to EtOH-ROL metabolic
competition.
The majority of dietary retinoid is stored as retinyl
ester (RE) mainly in hepatic stellate cells (HSCs).(35)
These stored retinoids are distributed as ROL or RE to
maintain serum retinoid concentration. The metabolism
of uptaken ROL utilizes a two-step oxidative processe,
in which medium-chain ADHs or retinol dehydroge-
nases catabolize ROL to retinaldehyde, followed by the
second oxidation facilitated by ALDH to produce
RA.(26) In particular to hepatocytes, ADH1 presumably
plays a critical role in biogenesis of RA because of its rel-
ative abundance.(36,37)
RA governs various aspects of cell biology, especially
in the regulation of cell differentiation and prolifera-
tion.(8) Thus, it is thought that RA has great influence
on cells continuously undergoing proliferation and dif-
ferentiation, such as professional immune cells. Indeed,
RA is known to potentiate adaptive immunity by regu-
lating T-cell proliferation, T helper 1-2 balancing, and
cytotoxicity, as well as modulating B-cell proliferation
and immunoglobulin production.(12) However, the role
of RA in intracellular innate antiviral immunity, in
which ISGs play a central role, has not been
determined.
The contribution of RA in ISG induction appears
not unique only to genes which nomenclature contains
“RA inducible.”(15,17,18) Indeed, a number of ISGs were
noted to be up-regulated in the gene list obtained from
transcriptome analysis of ATRA-treated leukemia
cells.(38) Our results indicated that the effect of RA in
ISG induction is gene specific rather than global up-
regulation (Fig. 6A), suggesting that RA unlikely indu-
ces ISGs by secretion of IFNs nor confers activation of
ISG induction pathways. In fact, we did not observe the
phosphorylation of STATs and interferon regulatory
factor 3 in ATRA-treated cells (data not shown) or
ADH1B expression in Huh7 cells (Supporting Fig.
5D,E). These notions collectively suggest that RA aug-
ments ISG expression at the gene promoter level. Our
bioinformatics analysis demonstrated that the occur-
rence of RARE-DR5 in promoters of randomly
selected genes was 2.11475 (-5,000 to1500). Based on
this number, we categorize ISGs into: (1) high DR5:
>5 4 (82 ISGs, average 4.904 DR5 occurrence); (2)
medium DR5: >52 and <4 (204 ISGs, average 2.441
DR5 occurrence); and (3) low DR5: <2 (160 ISGs,
average 0.688 DR5 occurrence; Supporting Table 1.
These results indicate that RA can influence the expres-
sion of up to 88% of ISGs at the promoter level. More-
over, the occurrence of RARE-DR5 is significantly
higher in nearly 20% of ISG promoters, further sug-
gesting the role of RA in ISG expression. However, we
have also noted that the RARE-DR5 frequency is not
well correlated to the degree of ISG expression
enhanced by the ADH-ALDH pathway (Fig. 6A; Sup-
porting Table 1). This can be explained either by the
cell-type-based differential response to RA or the dis-
crepancy between the bioinformatics algorithms and the
actual RAR-RXR occupancy. In fact, a study by others
has noted differential RA-gene regulation in a cell-
type-specific manner and have shown that genome-
wide RAR binding loci do not correspond to expression
of RA target genes.(39) The study attributed this dis-
crepancy to the diversity of RAR-RXR binding
sequence and/or chromatin topology.
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Our study found that the ADH-ALDH pathway
restricts HCV life cycle at either protein translation
and/or genome replication stage. Because a similar pat-
tern of HCV suppression was observed in IFN-treated
HCV-SGR cells (data not shown), it is possible to
speculate that the ISGs up-regulated by the ADH-
ALDH pathway cooperatively drive this phenomenon.
Because these two stages of viral life cycle have great
influence on each other, further investigation is
required in order to precisely define the mechanism of
how RA-regulated ISGs exhibit antiviral activities.
Our results also imply the possibility that catabolism
of RA by CYP2E1 may contribute to the impairments
of ISGs expression. In addition, others have reported
that the oxidative stress triggered by CYP2E1 impairs
the IFN-mediated ISG expression through inhibition
of STAT1 tyrosine phosphorylation,(40) indicating that
CYP2E1 impairs ISG expression through multiple
mechanisms. Furthermore, chronic liver diseases such
as ALD and HCV infection are known to cause
hypovitaminosis A as a result of the myofibroblastic
transformation of HSCs.(29,41) This mechanism likely
further aggravates the impairment of RA-regulated
ISG expression and thus explains the refractoriness to
IFN-based antiviral therapy among advanced liver dis-
ease patients.
In summary, our study provided novel insights on
the pathophysiology behind the synergistic liver disease
progression between HCV infection and ALD. The
insights obtained from our study are well applied to
the high-risk demographics of HCV infection, given
that nearly half of infected populations are heavy
drinkers.
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Supplemental Information 
Antibodies: The following antibodies were used: mouse anti-HCV NS5A;9E10 (a gift 
from C. Rice, Rockefeller University), rabbit anti-HCV NS3 (Abcam), rabbit anti-ADH1B 
(Abcam), rabbit anti-ADH4 (Aviva System Biology), ADH6 (Aviva System Biology), 
rabbit anti-ADHFE1 (GeneTex), rabbit anti-CYP2E1 (Abcam), rabbit anti-ALDH1A1 
(Abcam), rabbit anti-ALDH2 (Abcam), rabbit anti-ALDH4A1 (GeneTex), mouse anti-
GAPDH (GeneTex), Flag M2 (Sigma-Aldrich), IFIT1 (a gift from G. Sen, Cleveland 
Clinic), mouse anti-OAS1 (Kineta), mouse anti-IFITM1 (ProSci), rabbit anti-MX1 (Aviva 
System Biology), rabbit anti-RIG-I (Cell Signaling), rabbit anti-pIRF3 (Cell Signaling), 
mouse anti-IRF3 (Biolegend).    
 
Bioinformatics: Bioinformatics: ISG gene regulatory region analysis: The ExPlainTM 
v3.1 (www.biobase-international.com/explain) from BIOBASE Corporation(1) was used 
to scan for potential binding sites of RAR-RXR.  A list of 446 ISGs was formed based on 
the data set included in previous publications(2-4) and uploaded into ExPlain.  Match 
function was used to scan for possible binding sites of RAR-RXR in the [-5000, 500] 
regions around best-supported TSS for the 446 ISGs using position-based weight 
matrix V$RXRRAR_01 (M02272) with minimized false negatives (minFN) options. To 
obtain the background occurrence of RAR-RXR in human genome, 500 human genes 
were randomly selected and scanned using Match with the same parameters. All 446 
ISGs were used as enrichment background to minimize any enrichment biases.  
 
 
Nucleic Acid, Plasmid and Luciferase reporter assay: In vitro transcription of HCV 
genome or subgenomes was carried out using MEGAscript T7 transcription kit (Life 
Technologies). HCV PAMP RNA was generated similarly to previously described(5). 
Cellular RNA extraction was carried out using the RNAeasy kit (QIAGEN). QPCR was 
conducted using SYBR green-based one-step RT-qPCR method (Life Technologies). 
The relative gene expression was normalized to GAPDH values to obtain fold 
increases. The primer sequences for RT-qPCR and expression vector construction are 
available upon request. RT-qPCR array for the evaluation of Retinoic Acid target genes 
or ISG expression was conducted using Retinol Metabolism Panel (BioRad) or Type I 
IFN response panel  (QIAGEN) a two-step RT-QPCR. The obtained delta-CT values 
were analyzed with RT2 Profiler PCR Array Data Analysis version 3.5 and converted to 
a heat map after exclusion of redundancy, unrelated genes, or genes not expressed in 
the cells tested. The relative amplitude effect in log2 scale are listed in Table 2. The 
transient expression or lentiviral expression constructs were generated in pEF Myc/His 
Version C (Life Technologies) or pCDH-CMV-MCS-EF1-Puro (System Bioscience). All 
plasmids used in this study were propagated in DH5α under Ampicillin selection and 
purified with ZR plasmid miniprep or ZymoPure Plasmid Midiprep kit (Zymo Research). 
Luciferase based reporter assays were carried out with a RARE sequence driven firefly 
luciferase reporter construct with Dual Luciferase Assay kit (Promega)(6). The 
inducibility of RARE luciferase (Firefly) was normalized with the value from co-
transfected CMV promoter driven Renilla luciferase to determine Relative Luciferase 
Unit (RLU).  
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Supplemental Figure 1. Identification of liver dominant ADH/ALDH isoforms. A-B. 
Meta-analysis of ADH and ALDH expression: Nextbio was used to obtain the 
expression profiles of ADH and ALDH in public datasets. In Nextbio, high-quality public 
microarray dataset from GEO and other genomic data repositories were selected, 
normalized and pre-calculated for cross-study comparisons. Relative expression of a 
gene (fold-change) was calculated as the ratio between its expression in the selected 
tissue and its median expression across 52 tissue groups that are derived from 1067 
arrays. For ADH/ALDH expression analysis, 11 liver (GSE3526, GSE1133, GSE2361, 
GSE7307), 4 kidney (GSE1133, GSE2361, GSE7307), 3 small intestine (GSE2361, 
GSE7307), 2 heart (GSE2361, GSE7307), 2 smooth muscle (GSE1133), 2 whole brain 
(GSE1133) tissue samples were analyzed. Relative expression of multiple microarray 
probes for the same gene were consolidated using the median ratio. C. The relative 
expression abundance of flag-tagged ADH1B or CYP2E1 in Huh 7 cells were compared 
to that of freshly isolated primary human hepatocytes (PHH). The Huh7 cells were 
ectopically expressed with the indicated EtOH metabolizing enzymes for 24 hours. Then 
cell lysates were subjected to immunoblotting analysis for a relative abundance 
comparison with the cell lysates of freshly isolated PHH.     
 
Supplemental Figure 2. The effect of EtOH metabolic byproduct on HCV 
replication. A-B. Huh7 cells stably harboring HCV subgenomic replicon (JFH1 strain) 
were treated with acetaldehyde (A) or acetate (B) at indicated concentration for 48 
hours. Cell lysates were then subjected to IB analysis for the detection of HCV protein 
(NS3). Naïve Huh7 lysates were used as a negative control for HCV.  
Supplemental Figure 3. Distinct enzymatic activity of liver dominant ADH 
isoforms for the catabolism of ROL and its susceptibility to EtOH inhibition. A. 
Cell lysate expressing indicated ADH were incubated with NAD (3mM) in the presence 
or absence of ROL (100μM) to assess NAD-NADH conversion rate (μMoles/min/ml) via 
detection of 340/440nm fluorescent. B. Huh7 cells harboring HCV SGR was transduced 
with a control vector, ADH1B (Left Panel), or ADH4 (Right Panel) for 24 hours. Then 
cells were treated with the indicated concentration of EtOH for 24 hours followed by IB 
analysis of the indicated protein. The signal intensity of HCV NS3 was quantified with 
ImageJ software and the value was normalized to the signal from control vector 
transfected cells that were treated with PBS. The values are shown in %.  
 
Supplemental Figure 4. RA regulation of gene transcription through the activation 
of RARE DR5. A-C. Huh7 cells were co-transfected with indicated RARE luciferase and 
renilla luciferase reporter for 24 hours. Cells were then treated with ATRA treatment 
alone at 100nM (A), co-treated with EC23 (B), or 4310 (C) at the indicated 
concentration for 36 hours. Cell lysates are then subjected to dual luciferase assay.  
 
Supplemental Figure 5. RA augment both basal and induced expression of ISG in 
hepatocytes. A-B. Huh7 cells stably expressing ADH1B or control vector are monitored 
for the rate of cellular proliferation every 24 hours up to 96 hours (A) or subjected to 
trypan blue staining to determine the viable cells (B) at 72 hours.  C. Freshly isolated 
primay human hepatocytes were treated with vehicle (DMSO) or EC23 for 16 hours 
followed by IFNβ treatment for 8 hours at indicated dose. The RNA was subjected to 
RT-qPCR for the detection of indicated ISG. D-E. Huh7 cells were transfected with 
either ADH1B or control vector for 24 hours. 8 hours after expression vector 
transfection, cells were treated with EtOH (25mM) for 16 hours followed by HCV–PAMP 
RNA transfection (2μg/5x105cells)(D) or IFN-β (100IU/ml)(E). 16 hours after RNA 
transfection(D) or 1 hours after IFN-β treatment, cell lysates were subjected to IB 
analysis of the indicated protein expression analysis.   
 
Supplemental Figure 6. ADH-ALDH decreases cellular susceptibility to RNA virus 
infection. A-B. Huh7 cells stably expressing ADH1B or control vector were infected 
with Sendai Virus (SeV) at indicated infection titer for 24 hours. RNA and protein 
extracted were subjected to IB analysis (A) or QPCR (B) for the detection of viral 
product. *p<0.01. 
 
Supplemental Figure 7. Two distinct EtOH metabolizing pathways impair RA-
mediated gene regulation. A. Huh7 cells were co-transfected with an ADH1B 
expression vector, a RARE DR5 luciferase, and renilla luciferase reporter followed by 
treatment with ROL (1μM) and the indicated concentration of EtOH for 36 hours. Cell 
lysates were subjected to dual luciferase assay. *p<0.01. B. Huh 7 cells stably 
expressing ADH1B or control vector were treated with PBS or EtOH (25mM) for 40 
hours prior to IFNβ (50IU/ml) treatment for 8 hours. Extracted RNA was used for RT-
qPCR analysis of indicated ISGs expression. *p<0.01. C. Freshly isolated primary 
human hepatocytes were cultured in the presence of either DMSO (vehicle) or EtOH 
10mM for 24 hours followed by QPCR analysis of CYP2E1 expression change. GAPDH 
was used for the normalization and the calculation of fold index. *p<0.01. D. Huh7 cells 
were cotransfected with indicated CYP expression vectors, RARE DR5 luciferase, and 
renilla luciferase reporter for 36 hours. Cell lysates were subjected to dual luciferase 
assay. CYP26A1 that catabolize RA serves as a positive control. *p<0.01.  
 
Supplemental Table 1  
A. ISG containing high frequency of RARE DR5 in gene regulatory region (-5000 to +500) 
High # High # 
DEFB1 8 ABLIM3 4 
DUOXA2 7 APOL6 4 
IGFBP2 7 B2M 4 
LY6E 7 B4GALT5 4 
MX2 7 CMAH 4 
ODC1 7 CRP 4 
SCO2 7 CXCL9 4 
TREX1 7 CYorf15A 4 
TYMP 7 DDX60L 4 
ANKRD22 6 ELF1 4 
ARG2 6 ENPP1 4 
C22orf28 6 FUT4 4 
CCL2 6 GBA 4 
CLEC4D 6 GBP2 4 
FAM26F 6 GNB4 4 
GK 6 HLA-A 4 
LGALS9 6 HLA-DOB 4 
RAB4B 6 HLA-G 4 
RPL22 6 HMCN2 4 
ABTB2 5 IDO1 4 
ANGPTL1 5 IL17RB 4 
ARNTL 5 ISG20 4 
BCL2L14 5 KIAA0040 4 
BMI1 5 LGALS3 4 
BUB1 5 MT1M 4 
C1S 5 P2RY6 4 
CCR1 5 PARP14 4 
DDO 5 PDK1 4 
FAM134B 5 PLA2G2A 4 
FAM46C 5 RARB 4 
HEG1 5 RARRES3 4 
IL1R1 5 RASSF5 4 
IL28RA 5 RNF19B 4 
IMPA2 5 SAMHD1 4 
LAMP3 5 SP110 4 
MIA 5 ST3GAL4 4 
PIM3 5 TCF7L2 4 
PLA1A 5 TMEM140 4 
PLEK 5 TRAFD1 4 
PUS1 5 WHAMM 4 
SERPINE1 5 
  UPP2 5 
  
    
    
    
     
 
B. ISG containing average frequency of RARE DR5 in gene regulatory region (-5000 to +500) 
Average # Average # Average # Average # Average # 
APOBEC3A 3 MAB21L2 3 ADAMDEC1 2 IFI16 2 S100A8 2 
AQP9 3 MCL1 3 ALDH1A1 2 IFI35 2 SAMD4A 2 
ARHGEF3 3 MKX 3 AMPH 2 IFI44 2 SAMD9L 2 
ATF3 3 MOV10 3 ANG 2 IFI6 2 SERPING1 2 
BAG1 3 MSR1 3 ANKFY1 2 IFIT3 2 SLC15A3 2 
C15orf48 3 MT1G 3 APOL1 2 IFITM1 2 SLC1A1 2 
C3AR1 3 MT1H 3 APOL2 2 IFITM3 2 SMAD3 2 
C4orf33 3 MT1X 3 BATF2 2 IFNGR1 2 SOCS1 2 
CA7 3 MX1 3 BCL3 2 IL15RA 2 SPATS2L 2 
CARHSP1 3 MYOF 3 BLVRA 2 IL6ST 2 SPSB1 2 
CCL4 3 NAPA 3 BTN3A3 2 ISG15 2 SPTLC2 2 
CD38 3 NMI 3 C10orf10 2 KLHL17 2 SRGN 2 
CD53 3 NUP50 3 C1orf38 2 LAP3 2 STAT2 2 
CDKN1A 3 OAS2 3 C4orf32 2 LIPA 2 STEAP4 2 
CLEC2B 3 OPTN 3 C5orf27 2 LRG1 2 TLR2 2 
CLEC4E 3 OTUD4 3 CAPN8 2 MAFB 2 TMEM192 2 
CSF2RB 3 PARP12 3 CCDC92 2 MAP3K5 2 TMEM50A 2 
CSRNP1 3 PMAIP1 3 CCL19 2 MARCKS 2 TMEM51 2 
CTSO 3 PNRC1 3 CD163 2 MCOLN2 2 TMEM86A 2 
CYTH1 3 PSMB10 3 CD40 2 MEG3 2 TNFAIP3 2 
DCP1A 3 RABGAP1L 3 CD80 2 MICB 2 TNFRSF10A 2 
DDX58 3 RASGRP3 3 CEBPD 2 MYC 2 TRIM14 2 
DNAL4 3 RBCK1 3 CES1 2 MYD88 2 TRIM25 2 
DTX3L 3 RBP2 3 CHUK 2 NEURL3 2 TRIM46 2 
DUSP5 3 RNF34 3 CPT1A 2 NPAS2 2 TXNIP 2 
FCGR1A 3 SAA1 3 CTCFL 2 NRN1 2 VCAM1 2 
FNDC3B 3 SLC16A1 3 CTSS 2 NT5C3 2 VEGFC 2 
FNDC4 3 SLC25A28 3 CXCL10 2 OAS1 2 WARS 2 
G6PC 3 SNN 3 DUOXA1 2 OAS3 2 WNT10B 2 
GABBR1 3 SSBP3 3 EIF2AK2 2 PHF11 2 XAF1 2 
GAK 3 STARD5 3 ETV6 2 PI4K2B 2 ZNF263 2 
GCA 3 STAT1 3 FAM70A 2 PLIN2 2 ZNFX1 2 
GLRX 3 SUN2 3 FFAR2 2 PLSCR1 2 
  GPX2 3 TAGAP 3 FTSJD1 2 PPM1K 2 
  GZMB 3 TBX3 3 GBP1 2 PRIC285 2 
  HLA-DPA1 3 THBD 3 GBP4 2 PSMB8 2 
  IFI30 3 THOC4 3 GEM 2 PSMB9 2 
  IFI44L 3 TLR3 3 GJA4 2 RNASE4 2 
  IFIT1 3 TMEM49 3 GTPBP1 2 
    IFIT5 3 TNFSF10 3 HERC6 2 
    IRF1 3 UBD 3 HESX1 2 
    JUNB 3 UBE2L6 3 HLA-DRB1 2 
    LMO2 3 UNC93B1 3 HLA-F 2 
    LOC285194 3 VAMP5 3 HPSE 2 
    
  
XRN1 3 
      
  
ZBP1 3 
       
  
C. ISG containing low frequency of RARE DR5 in gene regulatory region (-5000 to +500) 
Low # Low # Low # Low # 
ADAR 1 IFIH1 1 TAP1 1 JAK2 0 
AGPAT9 1 IFIT2 1 TAP2 1 LGMN 0 
AHNAK2 1 IFITM2 1 TDRD7 1 MAFF 0 
AIM2 1 IL15 1 TIMP1 1 MXD1 0 
AKT3 1 IL1RN 1 TLK2 1 NCOA3 0 
APOBEC3B 1 IRF2 1 TNFSF13B 1 NDC80 0 
ATP10D 1 IRF7 1 TRIM22 1 NFIL3 0 
BAZ1A 1 ITIH4 1 TRIM31 1 PADI2 0 
BLZF1 1 LRRIQ3 1 TRIM38 1 PHF15 0 
CASP1 1 MAP2K5 1 TRIM5 1 PTMA 0 
CASP7 1 MAP3K14 1 UBE2D4 1 RGS1 0 
CCDC75 1 MASTL 1 ULK4 1 RSAD2 0 
CCL5 1 MAX 1 USP18 1 SELL 0 
CCL8 1 MB21D1 1 ZCCHC2 1 STAP1 0 
CD274 1 MS4A4A 1 ZNF385B 1 TNFAIP6 0 
CD74 1 MS4A6A 1 ACSL1 0 TP53 0 
CD9 1 MT1F 1 ADM 0 TRIM21 0 
CDC25B 1 MTHFD2L 1 ARL5B 0 
  CDK17 1 NAMPT 1 BST2 0 
  CMPK2 1 NLRC5 1 C5orf39 0 
  COMMD3 1 NOD2 1 C9orf91 0 
  CSDA 1 OASL 1 CCDC109B 0 
  CXCL11 1 OGFR 1 CCNA1 0 
  CYP1B1 1 PDGFRL 1 CCND3 0 
  DUSP6 1 PFKFB3 1 CCRL1 0 
  DYNLT1 1 PLAUR 1 CD69 0 
  EHD4 1 PLEKHA4 1 CFB 0 
  EPSTI1 1 PML 1 CHMP5 0 
  ETV7 1 PMM2 1 CREB3L3 0 
  EXT1 1 PNPT1 1 CRY1 0 
  FAM125B 1 PRAME 1 CX3CL1 0 
  FAM46A 1 PRKD2 1 DDIT4 0 
  FAM72B 1 PXK 1 DDX3X 0 
  FBXO6 1 RAB8B 1 DHX58 0 
  FST 1 RASSF4 1 EIF3L 0 
  FTSJD2 1 RIPK2 1 EPAS1 0 
  FZD5 1 RNF114 1 ERLIN1 0 
  GALNT2 1 RNF213 1 FAM111A 0 
  GBP5 1 RTP4 1 FKBP5 0 
  GCH1 1 SCARB2 1 FLJ39639 0 
  GLB1 1 SDS 1 GBP3 0 
  GMPR 1 SECTM1 1 GCNT1 0 
  GTPBP2 1 SERPINB9 1 HES4 0 
  HIST2H2AA 1 SIRPA 1 HK2 0 
  HLA-C 1 SLC22A23 1 HSH2D 0 
  HLA-DQB1 1 SLC25A30 1 IFI27 0 
  HLA-E 1 SLFN5 1 IL18BP 0 
  
  
SOCS2 1 IRF8 0 
    
Supplemental Table 2  
A. Relative gene expression fold index for Figure 4C (Log 2) 
 
Huh7 Control  Huh7 ADH1B 
Gene Symbol DMSO ROL (10
-6
M) DMSO 
DGAT1 1.000 1.838 3.471 
CYP1A2 1.000 2.239 32.832 
CYP2E1 1.000 2.575 5.065 
CYP2C18 1.000 5.177 140.220 
CYP3A7 1.000 2.612 24.024 
ADHFE1 1.000 0.259 3.794 
CYP2C19 1.000 0.858 22.446 
CYP2D6 1.000 0.763 26.970 
ALDH2 1.000 0.685 3.401 
GSTT1 1.000 0.089 3.323 
GSTM4 1.000 0.214 2.213 
CYP3A4 1.000 7.614 22.499 
XDH 1.000 25.570 508.804 
 
B. Relative gene expression fold index for Figure 4D (Log 2) 
 
PHH 
Gene Symbol DMSO RA 
DGAT1 1.000 3.178 
CYP1A2 1.000 36.480 
CYP2E1 1.000 5.134 
CYP2C18 1.000 3.645 
CYP3A7 1.000 4.195 
ADHFE1 1.000 5.126 
CYP2C19 1.000 8.189 
CYP2D6 1.000 3.493 
ALDH2 1.000 2.232 
GSTT1 1.000 4.402 
GSTM4 1.000 25.859 
CYP3A4 1.000 9.345 
XDH 1.000 5.261 
 
 
 
C. Relative gene expression fold index for Figure 6A (Log 2) 
Gene Symbol Mock Control Cell Mock ADH1B Cell HCV Control Cell HCV ADH1B Cell 
CCL5 1.000 2.563 13.618 5.134 
HLA-A 1.000 0.367 3.779 0.442 
IFI16 1.000 0.152 3.779 0.304 
IL10 1.000 1.255 0.613 0.497 
IFITM1 1.000 9.769 0.282 0.256 
IFI6 1.000 0.784 1.040 1.366 
NOS2 1.000 1.109 0.769 3.439 
TLR3 1.000 0.034 0.796 5.808 
TRAF3 1.000 1.157 1.129 2.577 
GBP1 1.000 1.399 1.838 3.366 
IFITM3 1.000 0.975 1.745 3.335 
TLR7 1.000 -1.247 9.948 27.024 
ISG20 1.000 1.006 0.500 1.923 
SOCS1 1.000 2.583 1.173 1.704 
CIITA 1.000 11.778 3.929 8.294 
TICAM1 1.000 3.823 1.758 3.149 
HLA-B 1.000 2.563 -1.006 5.134 
TLR8 1.000 2.563 0.994 5.134 
CASP1 1.000 2.619 0.260 5.608 
MX1 1.000 1.848 0.427 2.765 
IFIT1 1.000 1.633 0.636 2.497 
IFIT3 1.000 1.883 0.917 2.058 
IL6 1.000 2.463 0.747 3.921 
ISG15 1.000 2.094 0.675 3.317 
MYD88 1.000 2.924 1.035 2.765 
TIMP1 1.000 2.472 1.087 2.248 
IRF3 1.000 2.506 1.434 3.368 
IFIH1 1.000 1.648 -1.330 1.702 
TYK2 1.000 2.480 1.122 3.017 
IFIT3 1.000 1.883 0.917 2.058 
TNFSF10 1.000 2.061 0.729 2.428 
 
